The newest data, recently published in the BJU International by University College London and Imperial College Hospitals, UK, confirms very promising medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using HIFU for primary localized prostate cancer. From a total of 1’032 men treated between November 2005 and October 2017, freedom from radical treatment was 98%, 91% and 81% at 24, 60 and 96 months.
An exciting observation was made that during the study period there was an increase in the proportion of patients undergoing focal HIFU with Gleason 3 + 4 disease and with T2 stage disease as defined by multiparametric magnetic resonance imaging. Concurrently, there was a reduction over time in the proportion of patients undergoing re-treatment within 5 years of first treatment. This new evidence supports the hypothesis that advances in mpMRI, fusion and HIFU techniques improve clinical outcomes of focal HIFU therapy and make treatment more precise.
Read more in the open source publication: